What is a Lipschultz Ulcer?
Discussion Acute genital ulcers (AGU) are much less common in sexually-naive women than sexually experienced or active women. The differential diagnosis of AGU is large. For sexually active women Herpes simplex virus is the most common cause. Sexually transmitted infections are also included in this differential. In addition to the pain, AGUs can cause distress for the patient and family as possible sexual abuse must be considered. The differential diagnosis of AGU in non-sexually active women includes: Aphthosis Lipschutz ulcer Idiopathic Autoimmune or inflammatory diseases Behcet disease Bullous pemphigoid Inflammatory bowel disease MAGIC syndrome Pemphigus vulgaris Pyoderma gangrenosum Infection Epstein Barr virus Cytomegalovirus Influenza A Mumps Mycoplasma Paratyphoid Salmonella SARS-CoV-2 (COVID 19) – possibly? Medication Fixed drug eruption Non-steroidal anti-inflammatory drugs Trauma Irritation, chronic Trauma Learning Point Lipschutz ulcers (also known as ulcus vulvae acutum) were described in 1913 by Benjamin Lipschutz an Austrian microbiologist and dermatologist. They are ulcerations in young adolescents without a history of sexual activity. The painful acute ulcers are described as “…deep, necrotic with a purplish single or multiple margins, presenting in a mirror [kissing] pattern, and primary affect the medial face of the labia minora.” Fever and malaise commonly occur with it and other signs and symptoms can occur including aden...
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
Currently in fellowship doing bread/butter procedures (MBB, epidurals, PNB, few SCS/PNS trials, etc.) and just interviewed at a private practice spot where they do a lot of procedures that I will have not done any training in prior to graduating (e.g. IT pump, SI fusion, Vertiflex, Kypho, MILD, Discectomy, lots of SCS/PNS trials etc) and significant amount of "OR pain procedures" at a very busy practice seeing 30-40 pts/day - how many of you are commonly performing these procedures and are... private practice concern
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
CONCLUSIONS: This single practice study showed total patient contact was similar over both sample periods, but most contact in 2020 was virtual. Further longitudinal multi-practice studies to confirm these findings and describe future consultation patterns are needed to inform general practice service delivery post-COVID-19. PMID: 33032304 [PubMed - in process]
Publication date: Available online 1 October 2020Source: Academic RadiologyAuthor(s): Neo Poyiadji, Chad Klochko, Jeff LaForce, Manuel L. Brown, Brent Griffith
Authors: Siamashvili M, Davis S Abstract INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. AREAS COVERED: The authors describe current recommendations on the use of bromocriptine mesylate QR. Major efficacy and safety parameters of the late phase trials, including The Cycloset Safety Trial, have been identified and presented. EXPERT OPINION: Efficacy of bromocriptine mesylate QR monotherapy appears to be low but is compensated by favorable safety pr...
Publication date: 15 February 2021Source: Personality and Individual Differences, Volume 170Author(s): Brian W. Haas, Fumiko Hoeft, Kazufumi Omura
Publication date: December 2020Source: Journal of Functional Foods, Volume 75Author(s): Tingting Wang, Lin Zheng, Tiantian Zhao, Qi Zhang, Zhitong Liu, Xiaoling Liu, Mouming Zhao
More News: Acetaminophen | Austria Health | Autoimmune Disease | Behcet's Disease | Chemistry | Chronic Pain | Cold Sores | COVID-19 | Cytomegalovirus | Databases & Libraries | Dermatology | Diabetes | Diabetes Type 2 | Diabetic Ulcers | Education | Emergency Medicine | Endocrinology | Epidemics | Epidemiology | Genital Herpes | Girls | Headache | Herpes | Inflammatory Bowel Disease | Influenza | Laboratory Medicine | Learning | Lidoderm | Lortab | Microbiology | Migraine | Mumps | OBGYN | Pain | Pain Management | Pediatrics | Pemphigoid | Pemphigus | Salmonella | SARS | Sexual Abuse | Skin | STDs | Substance Abuse | Universities & Medical Training | Urinary Tract Infections | Vasculitis | Women